Merck & Co., Inc. $MRK Shares Sold by SlateStone Wealth LLC

SlateStone Wealth LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 4.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 117,597 shares of the company’s stock after selling 4,937 shares during the period. Merck & Co., Inc. makes up 1.2% of SlateStone Wealth LLC’s holdings, making the stock its 23rd biggest holding. SlateStone Wealth LLC’s holdings in Merck & Co., Inc. were worth $15,111,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. High Note Wealth LLC grew its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. during the 4th quarter valued at $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 2.0%

Shares of NYSE:MRK opened at $135.57 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a fifty day simple moving average of $125.25 and a 200 day simple moving average of $119.83. The firm has a market cap of $334.49 billion, a PE ratio of 108.46, a price-to-earnings-growth ratio of 5.73 and a beta of 0.19. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $135.68.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Wall Street Analyst Weigh In

A number of equities analysts have commented on MRK shares. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective on the stock. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. CICC Research began coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. Argus lifted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Fifteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $135.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.